Replies to post #40934 on Ariad Pharmaceuticals Inc fka ARIA

[grandma_of_jbraika]

I, patently silly, don't think vidpok45 added the following contents although he did say "A predicted 40 percent decrease in SAEs with a 15 mg. reduction in dose while maintaining efficacy is fantastic news if true."

– A 15 mg reduction in average daily dose intensity is predicted to lead to ~40%
reduction in the risk of arterial thrombotic events
– While predicted MCyR rates decrease with reduced dose intensity, substantial
responses (predicted and observed) occurred at lower doses. In addition, pts
who dose reduced after achieving MCyR were able to maintain response

http://congressposters.ariad.com/downloads/packages/37/ASH2013_PACE_DoseMod_poster_FINAL.pdf

You said,

ARIA’s poster did not include the phrase, while maintaining efficacy in the statement you referenced; you added that.

That's not patently silly.

[grandma_of_jbraika]

Each 15 mg/day reduction in dose intensity results in a predicted reduction of ~40% in the risk of an arterial thrombotic event.
http://t.co/MP4P3hn3FM

From 45 mg to 15 mg = 2 reductions. How many %40 reductions in the risk of an arterial thrombotic event can be expected?.
-----------

A predicted 40 percent decrease in SAEs with a 15 mg. reduction in dose while maintaining efficacy is fantastic news if true.

... Moreover, the statement in question pertains to arterial thrombotic SAEs, not SAEs in general.

That's not patently silly.

In my patently silly opinion, it's better than SAEs in general because arterial thrombotic SAEs seem to be the major concern. So I agree with vidpok45: it is fantastic news!